Hunan Xianshi Pharmaceutical Attracts Wide Attention at PHARMCHINA 91st National Pharmaceutical Fair in Nanjing
Release date:
2025-11-26
NANJING, Nov 26, 2025 — The 91st National Pharmaceutical Fair (PHARMCHINA) was held at Nanjing International Expo Center from November 19 to 21. The exhibition gathered over 2,000 top pharmaceutical enterprises and more than 100,000 industry practitioners, acting as a key platform for displaying industrial trends, showcasing corporate strengths and developing commercial cooperation.
Hunan Xianshi Pharmaceutical presented its complete product lineup at the event. Reliable product quality and favorable development prospects helped the firm gain extensive industry focus and positive feedback from cooperative partners, demonstrating its solid market competitiveness and sustainable development capacity.
Star Product Layout: Mature Core Products & Upcoming Pipeline Varieties
Xianshi Pharmaceutical’s booth focused on three major product segments: mature flagship medicine, core anti-influenza combination and upcoming pipeline products.
Flagship Product: Vitamin D3 Injection
Recommended by clinical guidelines for vitamin D deficiency treatment and included in unrestricted Class A national medical insurance, the product can be applied in nearly all clinical departments. Industry analysis predicts the relevant market will gradually concentrate among 2 to 3 leading manufacturers, and this injection is widely recognized as a high-growth blockbuster product.
Core Anti-Influenza Combination: Peramivir Injection & Oseltamivir Granules
The two anti-influenza medicines are essential clinical therapeutic options for flu treatment. Favored for stable curative effect and good market reputation, they maintain steady market demand and form a stable revenue base for the enterprise.
Upcoming Pipeline Products as New Growth Drivers
Multiple products including teriparatide injection, topiramate tablets and mannitol-sorbitol injection are proceeding through final approval procedures. Once launched, these new varieties will become important growth pillars to drive the company’s sales expansion.
Moving forward, Xianshi Pharmaceutical will stick to development driven by technological innovation and marketing optimization. The company plans to expand layout in clinical channels, retail pharmacies, OTC market and e-commerce sectors, and explore innovative cooperation modes with partners. By jointly building systematic healthcare solutions, Xianshi will cooperate with all industrial partners to realize win-win development in the healthcare industry.
Latest News
Share to
Hotline
Address
No. 19, Baizhu Road, Economic and Technological Development Zone, Liuyang City, Changsha, Hunan, China
Copyright © HUNAN XIANSHI PHARMACEUTICAL CO., LTD.
This site supports IPv4 IPv6 .